Dose-intensive weekly alternating chemotherapy for @entity1 with @entity151 : randomized trial, can it improve survival of XXXX with good prognostic factors?

@entity1 @entity632 @entity137 @entity1261 @entity900 @entity786 @entity1891 @entity3 @entity151 @entity3895
We conducted a randomized trial of dose-intensive weekly alternating chemotherapy ( @entity3895 /PE-W) and standard alternating chemotherapy ( @entity3895 /PE) in @entity151 ( @entity151 ) @entity1 with good prognostic factors. A total of 76 @entity1 with @entity151 was randomized. The @entity3895 /PE-W consisted of 4 alternating cycles of @entity786 : 500 mg/m2, @entity632 : 30 mg/m2, and @entity1891 : 1 mg/m2 (day 1) and @entity900 : 50 mg/m2 (day 8) and etoposide: 75 mg/m2 (days 8 and 9). The @entity3895 /PE consisted of 2 alternating cycles of @entity786 : 800 mg/m2, @entity632 : 50 mg/m2, and @entity1891 : 1.4 mg/m2 (day 1), @entity900 : 100 mg/m2 (day 22) and etoposide: 100 mg/m2 (days 22, 23 and 24). Eligibility criteria were no prior therapy, no active concomitant malignancy, ECOG PS of 0 or 1, age < or =75, adequate hematologic functions and no brain @entity3 . The complete response (CR) rate for @entity3895 /PE-W (14/38, 36.8%) was significantly higher than that for @entity3895 /PE (6/38, 15.8%, chi2; p=0. 032). However, the response rate in @entity1 on @entity3895 /PE-W (36/38, 94. 7%) was not significantly higher than the rate for @entity3895 /PE (31/38, 81. 6%, chi2; p=0.076). Progression-free survival for @entity1 on @entity3895 /PE-W was significantly longer than that of @entity1 on @entity3895 /PE (41.4 weeks vs. 21.3 weeks, log-rank; p=0.0007, generalized Wilcoxon; p=0.0034) as was overall median survival (67.0 weeks vs. 51.2 weeks, log-rank; p=0.028). Actual dose-intensity of @entity3895 /PE-W was 1.74 times that of @entity3895 /PE. Hematological @entity137 were equally frequent and @entity1261 contributes to treatment efficacy by allowing administration of dose-intensive chemotherapy. The @entity3895 /PE-W achieved a higher CR rate and longer survival, than the @entity3895 /PE.
